Health Care·Pharmaceuticals·$4.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.71 | N/A | -13.06% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.71 | N/A | -13.06% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed a cautious optimism about the future, focusing on their drug development initiatives. They acknowledged the EPS miss but reiterated their strategic goals.
Management highlighted ongoing efforts in drug development despite the EPS miss.
They emphasized their commitment to advancing their pipeline.
The earnings report shows that Crinetics Pharmaceuticals missed expectations on EPS, which may raise concerns among investors. However, the stock reacted positively, increasing by 5.01%, likely due to management's focus on their drug development pipeline. Investors may be encouraged by the company's long-term strategy despite the short-term EPS miss.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
DISNEY WALT CO
May 5, 2020